Medication use and kidney cancer risk: A population-based study

Area of Science:

• Oncology
• Pharmacology
• Epidemiology

Background:

• Limited data exists on medication exposure and kidney cancer risk.
• Previous studies may have biased classifications of cumulative medication exposure.
• Population-based studies are needed to clarify medication-cancer associations.

Purpose of the Study:

• To investigate the association between cumulative exposure to commonly prescribed medications and kidney cancer risk.
• To compare different methods of modeling medication exposure to reduce bias.
• To identify potential modifiable pharmacological interventions for kidney cancer prevention.

Main Methods:

• A population-based case-control study involving 10,377 kidney cancer cases and 35,939 controls (aged ≥66 years).
• Cumulative medication exposure assessed using prescription claims data.
• Exposure modeled using fractional polynomials (non-linear) and dichotomous (≥3 years vs. <3 years; ever vs. never) approaches.
• Conditional logistic regression used to estimate associations.

Main Results:

• Association directions were consistent, but magnitudes varied by analysis method.
• Increasing exposure to acetylsalicylic acid, selective serotonin reuptake inhibitors (SSRIs), and proton-pump inhibitors (PPIs) was linked to reduced kidney cancer risk.
• Increasing exposure to antihypertensive drugs was associated with increased kidney cancer risk.

Conclusions:

• Findings suggest commonly prescribed medications can influence kidney cancer risk.
• Further research is warranted to explore medication effects on carcinogenesis.
• Identifies potential targets for pharmacological interventions to mitigate kidney cancer risk.